Download Free European Drug Index Book in PDF and EPUB Free Download. You can read online European Drug Index and write the review.

Many health care providers are frequently dealing with problems related to the identification and interpretation of medicines and prescriptions of foreign origin. Health authorities, customs and travel agencies also encounter such problems, which are related to the increasing mobility of the European population. Thus the need for a European Drug Index is obvious. The EDI provides extended information for practitioners confronted with the enormous number of drug names available on the European pharmaceutical market. This market is increasing due to the rapidly changing palette of countries and economic restrictions in Europe. The listings have been derived from drug data sources from the increased number of participating countries in this second edition. Each item starts with a trade name, in alphabetical order, followed by (depending on the original source) dosage forms, strength, volume (if applicable), and generic name(s) of the active principle(s) in a random sequence. The item is concluded by the Anatomical Therapeutic Chemical (ATC) classification (when made available by the original source) and a code for the country of origin.
This fourth edition of the European Drug Index provides information about drugs available on the European market arranged alphabetically by trade name, including
Designed for use as a self-study text, as a course text in more formal instruction programs, or as a refresher for the busy professional, the book includes valuable background data on legal and regulatory issues, as well as pharmaceutical technology.
Mind-altering drugs such as cannabis, cocaine, heroin and others are illegal in many parts of the world, but distinct approaches for dealing with the question of illegal drug use have been developed country by country. In this book Tim Boekhout van Solinge describes the different approaches that have been adopted to dealing with the problem, with particular reference to the experience of France, the Netherlands and Sweden. He explores the justifications and rationalizations for the divergent, often contradictory attitudes and systems that have been developed, and concludes that differing national cultural traditions for handling social problems have greatly influenced the ways in which illicit drug use have been dealt with.
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures.
This title combines all of the human and veterinary Regulations, Directives and guidance for medicinal products used by the pharmaceutical industry as their main source when manufacturing and distributing medicinal products in the European Union.
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
Medical devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the FDA 510(k) process. In recent years, individuals and organizations have expressed concern that the 510(k) process is neither making safe and effective devices available to patients nor promoting innovation in the medical-device industry. Several high-profile mass-media reports and consumer-protection groups have profiled recognized or potential problems with medical devices cleared through the 510(k) clearance process. The medical-device industry and some patients have asserted that the process has become too burdensome and is delaying or stalling the entry of important new medical devices to the market. At the request of the FDA, the Institute of Medicine (IOM) examined the 510(k) process. Medical Devices and the Public's Health examines the current 510(k) clearance process and whether it optimally protects patients and promotes innovation in support of public health. It also identifies legislative, regulatory, or administrative changes that will achieve the goals of the 510(k) clearance process. Medical Devices and the Public's Health recommends that the U.S. Food and Drug Administration gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices. According to the report, the FDA's finite resources are best invested in developing an integrated premarket and postmarket regulatory framework.